Share based payments - Summary of subscription rights outstanding and exercisable (Details)
|
|
|
12 Months Ended |
|
|
Oct. 01, 2024
shares
|
May 16, 2024
shares
|
Dec. 31, 2024
EquityInstruments
€ / shares
|
Dec. 31, 2023
EquityInstruments
€ / shares
|
Dec. 31, 2022
EquityInstruments
€ / shares
|
Dec. 31, 2021
EquityInstruments
€ / shares
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 73.19
|
€ 77.93
|
€ 83.12
|
€ 92.69
|
| Outstanding at the beginning of the year |
|
|
11,472,520
|
10,816,856
|
8,579,837
|
|
| Granted during the year |
41,000
|
1,340,000
|
1,381,000
|
1,538,400
|
3,127,239
|
|
| Exercised during year |
|
|
|
(61,560)
|
(282,790)
|
|
| Forfeited during the year |
|
|
(547,911)
|
(544,676)
|
(607,430)
|
|
| Expired during the year |
|
|
(394,500)
|
(276,500)
|
|
|
| Outstanding at the end of the year |
|
|
11,911,109
|
11,472,520
|
10,816,856
|
|
| Exercisable |
|
|
5,182,941
|
5,836,538
|
2,574,218
|
1,751,013
|
| Subscription rights |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 73.19
|
€ 77.93
|
€ 83.1
|
|
| Outstanding at the beginning of the year |
|
|
11,472,520
|
10,816,856
|
|
|
| Granted during the year |
|
|
1,381,000
|
|
|
|
| Forfeited during the year |
|
|
(547,911)
|
|
|
|
| Expired during the year |
|
|
(394,500)
|
|
|
|
| Outstanding at the end of the year |
|
|
11,911,109
|
11,472,520
|
10,816,856
|
|
| Exercisable |
|
|
5,182,941
|
|
|
|
| 2016 allocated on June 2016 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 46.1
|
|
|
|
| Outstanding at the beginning of the year |
|
|
325,500
|
|
|
|
| Expired during the year |
|
|
(325,500)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
325,500
|
|
|
| 2016 RMV allocated on June 2016 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 46.1
|
|
|
|
| Outstanding at the beginning of the year |
|
|
69,000
|
|
|
|
| Expired during the year |
|
|
(69,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
|
69,000
|
|
|
| 2016 (B) allocated on January 2017 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 62.5
|
|
|
|
| Outstanding at the beginning of the year |
|
|
10,000
|
|
|
|
| Outstanding at the end of the year |
|
|
10,000
|
10,000
|
|
|
| Exercisable |
|
|
10,000
|
|
|
|
| 2017 allocated on May 2017 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 80.57
|
|
|
|
| Outstanding at the beginning of the year |
|
|
585,000
|
|
|
|
| Outstanding at the end of the year |
|
|
585,000
|
585,000
|
|
|
| Exercisable |
|
|
585,000
|
|
|
|
| 2017 RMV allocated on May 2017 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 80.57
|
|
|
|
| Outstanding at the beginning of the year |
|
|
122,500
|
|
|
|
| Forfeited during the year |
|
|
(17,500)
|
|
|
|
| Outstanding at the end of the year |
|
|
105,000
|
122,500
|
|
|
| Exercisable |
|
|
105,000
|
|
|
|
| 2018 allocated on April 2018 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 79.88
|
|
|
|
| Outstanding at the beginning of the year |
|
|
964,995
|
|
|
|
| Forfeited during the year |
|
|
(35,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
929,995
|
964,995
|
|
|
| Exercisable |
|
|
929,995
|
|
|
|
| 2018 RMV allocated on April 2018 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 79.88
|
|
|
|
| Outstanding at the beginning of the year |
|
|
132,500
|
|
|
|
| Forfeited during the year |
|
|
(15,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
117,500
|
132,500
|
|
|
| Exercisable |
|
|
117,500
|
|
|
|
| 2019 allocated on April 2019 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 95.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
1,208,240
|
|
|
|
| Forfeited during the year |
|
|
(63,250)
|
|
|
|
| Outstanding at the end of the year |
|
|
1,144,990
|
1,208,240
|
|
|
| Exercisable |
|
|
1,144,990
|
|
|
|
| 2019 RMV allocated on April 2019 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 95.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
177,250
|
|
|
|
| Forfeited during the year |
|
|
(23,750)
|
|
|
|
| Outstanding at the end of the year |
|
|
153,500
|
177,250
|
|
|
| Exercisable |
|
|
153,500
|
|
|
|
| 2020 allocated on April 2020 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 168.42
|
|
|
|
| Outstanding at the beginning of the year |
|
|
1,369,617
|
|
|
|
| Forfeited during the year |
|
|
(53,925)
|
|
|
|
| Outstanding at the end of the year |
|
|
1,315,692
|
1,369,617
|
|
|
| Exercisable |
|
|
1,315,692
|
|
|
|
| 2020 RMV allocated on April 2020 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 168.42
|
|
|
|
| Outstanding at the beginning of the year |
|
|
193,300
|
|
|
|
| Forfeited during the year |
|
|
(14,125)
|
|
|
|
| Outstanding at the end of the year |
|
|
179,175
|
193,300
|
|
|
| Exercisable |
|
|
179,175
|
|
|
|
| 2021 BE allocated on April 2021 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 64.76
|
|
|
|
| Outstanding at the beginning of the year |
|
|
1,032,606
|
|
|
|
| Forfeited during the year |
|
|
(17,573)
|
|
|
|
| Outstanding at the end of the year |
|
|
1,015,033
|
1,032,606
|
|
|
| 2021 RMV allocated on April 2021 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 64.76
|
|
|
|
| Outstanding at the beginning of the year |
|
|
226,296
|
|
|
|
| Forfeited during the year |
|
|
(7,371)
|
|
|
|
| Outstanding at the end of the year |
|
|
218,925
|
226,296
|
|
|
| Exercisable |
|
|
109,258
|
|
|
|
| 2021 ROW allocated on April 2021 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 64.76
|
|
|
|
| Outstanding at the beginning of the year |
|
|
667,496
|
|
|
|
| Forfeited during the year |
|
|
(76,046)
|
|
|
|
| Outstanding at the end of the year |
|
|
591,450
|
667,496
|
|
|
| Exercisable |
|
|
295,498
|
|
|
|
| 2022 (A) allocated on January 2022 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 46.18
|
|
|
|
| Outstanding at the beginning of the year |
|
|
30,000
|
|
|
|
| Outstanding at the end of the year |
|
|
30,000
|
30,000
|
|
|
| Exercisable |
|
|
15,000
|
|
|
|
| 2022 (B) allocated on January 2022 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 50
|
|
|
|
| Outstanding at the beginning of the year |
|
|
1,000,000
|
|
|
|
| Outstanding at the end of the year |
|
|
1,000,000
|
1,000,000
|
|
|
| 2022 BE allocated on May 2022 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 57.46
|
|
|
|
| Outstanding at the beginning of the year |
|
|
817,828
|
|
|
|
| Forfeited during the year |
|
|
(13,596)
|
|
|
|
| Outstanding at the end of the year |
|
|
804,232
|
817,828
|
|
|
| 2022 BE allocated on August 2022 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 51.58
|
|
|
|
| Outstanding at the beginning of the year |
|
|
78,000
|
|
|
|
| Outstanding at the end of the year |
|
|
78,000
|
78,000
|
|
|
| 2022 RMV allocated on May 2022 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 57.46
|
|
|
|
| Outstanding at the beginning of the year |
|
|
203,464
|
|
|
|
| Forfeited during the year |
|
|
(4,395)
|
|
|
|
| Outstanding at the end of the year |
|
|
199,069
|
203,464
|
|
|
| Exercisable |
|
|
49,672
|
|
|
|
| 2022 ROW allocated on May 2022 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 57.46
|
|
|
|
| Outstanding at the beginning of the year |
|
|
705,500
|
|
|
|
| Forfeited during the year |
|
|
(74,400)
|
|
|
|
| Outstanding at the end of the year |
|
|
631,100
|
705,500
|
|
|
| Exercisable |
|
|
157,661
|
|
|
|
| 2022 BE/ROW allocated on August 2022 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 51.58
|
|
|
|
| Outstanding at the beginning of the year |
|
|
60,000
|
|
|
|
| Outstanding at the end of the year |
|
|
60,000
|
60,000
|
|
|
| Exercisable |
|
|
15,000
|
|
|
|
| 2023 BE allocated on May 2023 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 35.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
609,028
|
|
|
|
| Forfeited during the year |
|
|
(15,778)
|
|
|
|
| Outstanding at the end of the year |
|
|
593,250
|
609,028
|
|
|
| 2023 RMV allocated on May 2023 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 35.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
102,500
|
|
|
|
| Forfeited during the year |
|
|
(2,500)
|
|
|
|
| Outstanding at the end of the year |
|
|
100,000
|
102,500
|
|
|
| 2023 ROW allocated on May 2023 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 35.11
|
|
|
|
| Outstanding at the beginning of the year |
|
|
561,900
|
|
|
|
| Forfeited during the year |
|
|
(65,000)
|
|
|
|
| Outstanding at the end of the year |
|
|
496,900
|
561,900
|
|
|
| 2023 BE allocated on June 2023 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 38.58
|
|
|
|
| Outstanding at the beginning of the year |
|
|
200,000
|
|
|
|
| Outstanding at the end of the year |
|
|
200,000
|
200,000
|
|
|
| 2023 ROW allocated on November 2023 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 32.99
|
|
|
|
| Outstanding at the beginning of the year |
|
|
20,000
|
|
|
|
| Outstanding at the end of the year |
|
|
20,000
|
20,000
|
|
|
| 2024 BE allocated in May 2024 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 26.9
|
|
|
|
| Granted during the year |
|
|
679,000
|
|
|
|
| Forfeited during the year |
|
|
(11,202)
|
|
|
|
| Outstanding at the end of the year |
|
|
667,798
|
|
|
|
| 2024 RMV allocated in May 2024 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 26.9
|
|
|
|
| Granted during the year |
|
|
21,500
|
|
|
|
| Outstanding at the end of the year |
|
|
21,500
|
|
|
|
| 2024 ROW allocated on May 2024 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 26.9
|
|
|
|
| Granted during the year |
|
|
639,500
|
|
|
|
| Forfeited during the year |
|
|
(37,500)
|
|
|
|
| Outstanding at the end of the year |
|
|
602,000
|
|
|
|
| 2024 BE allocated in October 2024 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 25.88
|
|
|
|
| Granted during the year |
|
|
3,500
|
|
|
|
| Outstanding at the end of the year |
|
|
3,500
|
|
|
|
| 2024 ROW allocated in October 2024 |
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
| Exercise Price | € / shares |
|
|
€ 25.88
|
|
|
|
| Granted during the year |
|
|
37,500
|
|
|
|
| Outstanding at the end of the year |
|
|
37,500
|
|
|
|